Piramal deal will give Abbott India size Piramal, who is the chairman of Piramal Healthcare, said “the valuation of about nine times shows the. It took four hours for Ajay Piramal to negotiate a whopping $ billion valuation for his generics business with Abbott. Just how did he pull it off. Abbott to pay $ billion for unit of India’s Piramal Disagreements over valuation have prevented more deals from getting done. Abbott.
|Published (Last):||28 October 2008|
|PDF File Size:||16.39 Mb|
|ePub File Size:||9.70 Mb|
|Price:||Free* [*Free Regsitration Required]|
The Abbott-Piramal combine reports to him, but he notes it will be run as a standalone business unit after piramla merger takes effect later this year. BOis booming as governments battle rising healthcare costs.
Foul language Slanderous Inciting hatred against a certain community Others. But investors remain disappointed in the absence of an open offer.
Abbott to pay 17K crore for Piramal generics business – The Economic Times
To see your saved stories, click on link hightlighted in bold. The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in Disagreements over valuation have prevented more deals from getting sbbott.
Get instant notifications from Pirsmal Times Allow Not now You can switch off notifications anytime using browser settings. Piramal Healthcare will retain its contract manufacturing, critical care, over-the-counter drugs — valuatioon of which cumulatively generate Rs 1,crore revenues, but where margins are much lower.
The materialisation of this deal will also encourage buyers loosen their wallets. Increased funding expands the scope for drug research, but that alone is not enough; other pieces have to fall in place, Piramal notes. It makes a lot of sense if they can pull off all the integration issues. These other players are not even interested in doing that.
Seven years after Piramal deal, Abbott way off revenue target
Mumbai-based Piramal said it would consider paying a special dividend and would use deal proceeds to invest in its remaining businesses and pay down debt. Its other businesses include third-party manufacturing and pathology laboratories. Unlike other pharmaceutical acquisitions that have been targeted at buying Indian generic capacity to service Western and emerging markets, the Abbott-Piramal deal is primarily focused on the domestic market, according to Mumbai-based business magazine Business India.
It is paying roughly 8. That is one reason pharmaceutical multinationals are doing deals with the relatively small number of well established Indian companies that have met international standards in manufacturing.
But that is also changing, she says. Some said prices of medicines will go up. NIFTY 50 10, Piramal Healthcare also retains custom manufacturing, over-the-counter consumer products, diagnostic medical devices and services and clinical research, among other activities.
Read more on Piramal. All the same, the West continues to dominate pharmaceutical innovation, and companies in India and other emerging markets could play a supportive role, according to Danzon.
According to Wharton faculty and industry experts, changing global business models and the resources needed to develop blockbuster drugs are propelling Indian companies to join forces with multinationals through strategic alliances or as targets for acquisitions.
L as possible buyers. Since then, further pharmaceutical deals have been expected, as global majors search for growth and low-cost production of generics, as patents on major branded drugs are set to expire. My Saved Articles Sign in Sign up.
Abbott to pay 17K crore for Piramal generics business
The Indian unit of Abbott, which is a listed valuatiin, has a 2. The potential to expand with very high priced specialty products is seriously limited.
Chaudhuri acknowledges those new realities, but with a patriotic tinge. In fact, 10 days before the Piramal acquisition, Abbott announced a licensing and supply deal with Indian pharmaceutical company Zydus Cadila. Growth Through Overseas Expansion Globalization is not just for manufacturers. Based in Abbott Park, Ill. However, companies like Abbott and others getting into new generic drug markets must be watchful of the changing lay of the land there as well, according to Danzon.
It will, however, continue research in drug discovery through an affiliate company. There is intense speculation that Mr Piramal will buy companies in some of these segments. Fill in your details: As a global MNC, Abbott does. Drag according to your convenience.